Outlook Therapeutics to Present at the H.C. Wainwright BioConnect Conference

Rhea-AI Summary

Outlook Therapeutics, a biopharmaceutical company, has announced that CEO C. Russell Trenary III will participate in the upcoming H.C. Wainwright BioConnect Conference from January 10-13, 2022. The company is developing ONS-5010/LYTENAVA™, the first FDA-approved ophthalmic formulation of bevacizumab for retinal indications, including wet AMD and DME. A video webcast of the fireside chat will be available on-demand starting January 10, 2022. Outlook Therapeutics aims to submit ONS-5010 to the U.S. FDA, potentially becoming the first approved ophthalmic bevacizumab in several key markets.

ISELIN, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that C. Russell Trenary III, President and Chief Executive Officer of Outlook Therapeutics, will participate in a fireside chat at the virtual H.C. Wainwright BioConnect Conference taking place January 10-13, 2022.

A video webcast of the fireside chat will be available for viewing on-demand beginning Monday, January 10, 2022, at 7:00 AM ET for those registered for the conference and will be accessible on the Events page of the Investors section of the Outlook Therapeutics website, outlooktherapeutics.com.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to submit ONS-5010 ophthalmic bevacizumab to the U.S. FDA as a BLA under the PHSA 351(a) regulatory pathway. For more information, please visit www.outlooktherapeutics.com.

CONTACTS:
Media Inquiries:
Harriet Ullman
Vice President
LaVoie Health Science
T: 617-669-3082
hullman@lavoiehealthscience.com

Investor Inquiries:       
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247 
OTLK@jtcir.com

FAQ

What is the significance of Outlook Therapeutics' participation in the H.C. Wainwright BioConnect Conference?

Outlook Therapeutics' CEO will discuss their developments in ocular therapies, particularly regarding FDA-approved treatments.

When will the video webcast of the fireside chat be available?

The webcast will be available on-demand starting January 10, 2022, at 7:00 AM ET.

What is ONS-5010 and its potential market impact?

ONS-5010, also known as LYTENAVA™, is poised to be the first FDA-approved ophthalmic bevacizumab for treating retinal diseases.

What retinal conditions does Outlook Therapeutics aim to address with ONS-5010?

ONS-5010 targets conditions such as wet AMD, DME, and BRVO.

What regulatory pathway is Outlook Therapeutics using for ONS-5010 submission?

The company plans to submit ONS-5010 to the U.S. FDA as a Biologics License Application under the PHSA 351(a) pathway.